Mutations were found in 70% of patients, with 53% of patients possessing driver mutations and 17 genes showing mutations in more than 2% of patients.
It’s useful to be aware of misconceptions your patients might have about leukemia. We debunk 6 common myths.
Four-year cumulative risk of any relapse lower for dasatinib in the context of intensive chemotherapy
For the entire cohort of pediatric patients with standard-risk acute lymphoblastic leukemia, overall survival at 6 years was greater than 95%.
Median progression-free survival was 34.2 months in patients who received ofatumumab and 16.9 months in patients who received no additional treatment.
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
The analysis revealed that Medicare beneficiaries had different treatment outcomes compared with the trial participants.
Improvement in median overall survival from 5.8 years in 1995 to 2011 to not reached in 2009 to 2017.
Risk score identifies risk among patients with acute leukemia treated with anthracyclines before chemo
Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
Induction therapy with blinatumomab did not appear to confer a survival benefit, though undergoing stem cell transplant did.
Eligibility criteria for this study included intermediate- or high-risk cytogenetics, and CR or CR with incomplete count recovery following induction chemotherapy.
There is an increasing focus on using the achievement of undetectable MRD in bone marrow as a clinical trial end point in patients with CLL.
Older age, body mass index above 30, and development of drug-induced diabetes mellitus were associated with increased risk for type 2 diabetes mellitus.
Among patients treated with an acute lymphoblastic leukemia induction regimen, 72% achieved end-of-induction complete remission.
This study addressed the dearth of information on the incidence of psychiatric disorders related to corticosteroid-containing treatment in patients with hematologic malignancies.
Researchers sought to determine if nonmyeloablative HSCT conditioning was noninferior to myeloablative approaches in more vulnerable patients with AML.
Patients receiving ibrutinib for chronic lymphocytic leukemia experienced an average weight gain of 2.4 kg at 1 year after therapy initiation.
Patients with acute myeloid leukemia and myelodysplastic syndromes reported similar quality of life irrespective of the conditioning regimen the received.
In patients with complete response at transplant, age was found to be the only predictor of clinical outcomes.
This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
Exercise tolerance was found to be associated with verbal fluency, dominant motor speed, and math academics, among other neurocognitive metrics.
Central nervous system relapse rates in pediatric acute lymphoblastic leukemia can be reduced with additional early doses of intrathecal chemotherapy.
Researchers assessed whether high platelet counts in pediatric patients with chronic myeloid leukemia resulted in thrombosis or bleeding.
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
The response rate to 19-28z CAR-T therapy was 100% for those with pretreatment MRD who received preconditioning chemotherapy with high-dose cyclophosphamide.
The risk may be transient, as immune function recovered in late phases of treatment.
Researchers conducted a meta-analysis of 23 studies to determine the influence of measurable residual disease on survival outcomes.
Researchers analyzed long-term safety and efficacy data from patients treated with ibrutinib or ofatumumab in the phase 3 RESONATE trial.
Using EQ-5D and PedsQL, researchers determined the long-term effect of tisagenlecleucel treatment on quality of life for pediatric and young patients with R/R B-cell ALL.
Approximately one-third of patients in each treatment group experienced symptoms of depression and anxiety during treatment.
It is hypothesized that BAFF-R could prevent the emergence of CD19-based antigen loss.
The risk for second primary malignancy appeared to increase over time in survivors of chronic lymphocytic leukemia compared with the general population.
Patients received 50 mg dasatinib daily and demonstrated 2-year rates of overall and event-free survival of 100%.
Researchers conducted a meta-analysis to evaluate possible associations between certain genetic variants and risk for acute lymphoblastic leukemia.
Older age at diagnosis, white race, and body mass index below the fifth percentile were associated with low bone mineral density.
Factors associated with survival in chronic myeloid leukemia diagnosed in advanced phase or blast crisis included blast count, age, and hemoglobin level.
Of patients who experienced vincristine-induced neuropathy, approximately half were identified as having undernutrition.
Infections occurred in 33 of 54 patients for whom data were available, and 80% of infections were treated in an outpatient setting.
Although the 7 + 3 regimen has been the standard of care for acute myeloid leukemia for decades, it may be time to reassess its value and utility.
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
A retrospective study evaluated the incidence of respiratory adverse events in children and adolescents with AML who received induction chemotherapy.
Presence of a complex karyotype did not affect progression-free or overall survival.
Using validated assessment tools, researchers compared patients’ perceptions of HRQOL while undergoing treatment for CML with 1 of 2 TKIs.
Researchers are assessing the value and safety of discontinuing TKI therapy in patients with chronic phase CML who have achieved deep molecular response.
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
Over half of patients with
TP53-mutated acute myeloid leukemia who received the combination therapy experienced a response.
In a review article, researchers discussed maintenance treatment strategies using chemotherapy, immunotherapy, targeted small molecules, and more.
Nilotinib was associated with high adherence to treatment and fairly high quality of life, and nearly all evaluated patients achieved a major molecular response.
Certain malignancies, younger age at diagnosis, and multiple affected relatives were all associated with increased familial relative risks.